• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Intensive Care Unit requirements in patients treated with immune checkpoint inhibitors

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Cooksley, Timothy J
    Weaver, Jamie M
    Haji-Michael, Philip
    Affiliation
    Departments of Acute Medicine, Medical Oncology and Critical Care, The Christie, Wilmslow Road, Manchester, UK.
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Objective: To determine the proportion of emergency patients treated with immune checkpoint inhibitors (ICIs) that require critical care admission and their requirements. Design: Prospective case series. Methods: Analysis of acutely unwell patients treated with ICIs attending a tertiary UK cancer hospital between May 2018 and May 2022. The primary outcome measure was the percentage of patients treated with ICI therapy requiring ICU admission. The secondary outcome measure was whether this need was driven by an immune-mediated toxicity. Results: Eighteen (1.2%) patients of the 1561 acutely admitted patients treated with ICI therapy required an admission to ICU. Ten (55.5%) patients were admitted due to an immune-mediated toxicity; 4 due to pneumonitis and 4 due to myasthenia gravis. Seven of 10 survived their ICU admission with 6 surviving at least 6 month post ICU discharge. Conclusions: Only a small minority of emergency admissions in patients treated with ICIs require admission to ICU. This series adds further evidence that patients with organ failure due to immune-mediated toxicity may achieve good outcomes from ICU admission.
    Citation
    Cooksley T, Weaver JMJ, Haji-Michael P. Intensive Care Unit requirements in patients treated with immune checkpoint inhibitors. QJM : monthly journal of the Association of Physicians. 2022 Nov 15. PubMed PMID: 36377790. Epub 2022/11/16. eng.
    Journal
    QJM
    URI
    http://hdl.handle.net/10541/625773
    DOI
    10.1093/qjmed/hcac258
    PubMed ID
    36377790
    Additional Links
    https://dx.doi.org/10.1093/qjmed/hcac258
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1093/qjmed/hcac258
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.
    • Authors: Lin L, Houwink API, van Dieren JM, Wolthuis EK, van Thienen JV, van der Heijden MS, Haanen JBAG, Beijnen JH, Huitema ADR
    • Issue date: 2024 Jun
    • Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series.
    • Authors: Rajendram P, Torbic H, Duggal A, Campbell J, Hovden M, Dhawan V, Pastores SM, Gutierrez C
    • Issue date: 2021 Oct
    • ICU admission for solid cancer patients treated with immune checkpoint inhibitors.
    • Authors: Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, Seguin A, Kouatchet A, Delaunay M, Debieuvre D, Duchemann B, Rousseau-Bussac G, Nyunga M, Grimaldi D, Levrat A, Azoulay E, Lemiale V
    • Issue date: 2023 Apr 18
    • Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE).
    • Authors: Ahern E, Allen MJ, Schmidt A, Lwin Z, Hughes BGM
    • Issue date: 2021 Apr
    • Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    • Authors: Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler AH, Gaeta S
    • Issue date: 2021 Aug
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.